Showing results (61-70 of 137) with videos related to
Sort By:
Pageof 14
Clinical Lymphoma, Myeloma & Leukemia|September 22, 2020
Antifungal Stewardship in Hematology: Reflection of a Multidisciplinary Group of ExpertsMauricette Michallet, Mohamad Sobh, Gilbert Deray, et al.Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|December 25, 2015
Does Epoetin Beta Still Have a Place in Peginterferon Alpha-2a Plus Ribavirin Treatment Strategies for Chronic Hepatitis C?Pascal Veillon, Isabelle Fouchard-Hubert, Dominique Larrey, et al.Journal of Hepatology|April 24, 2012
Excessive alcohol consumption after liver transplantation impacts on long-term survival, whatever the primary indicationStéphanie Faure, Astrid Herrero, Boris Jung, et al.Journal of Viral Hepatitis|August 19, 2020
Cannabis use is associated with a lower risk of diabetes in chronic hepatitis C-infected patients (ANRS CO22 Hepather cohort)Tangui Barré, Marie Libérée Nishimwe, Camelia Protopopescu, et al.Pharmacoepidemiology and Drug Safety|November 29, 2022
Impact of direct-acting antiviral treatment for hepatitis C on cardiovascular diseases and extrahepatic cancersLaurent Lam, Hélène Fontaine, Nathanael Lapidus, et al.Antimicrobial Agents and Chemotherapy|April 9, 2014
SILEN-C3, a phase 2 randomized trial with faldaprevir plus pegylated interferon α-2a and ribavirin in treatment-naive hepatitis C virus genotype 1-infected patientsDouglas Dieterich, Tarik Asselah, Dominique Guyader, et al.Journal of Hepatology|December 15, 2010
A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitisVlad Ratziu, Victor de Ledinghen, Fréderic Oberti, et al.Liver International : Official Journal of the International Association for the Study of the Liver|October 17, 2015
The role of genetic factors in patients with hepatocellular carcinoma and iron overload - a prospective series of 234 patientsNatalie Funakoshi, Iphigénie Chaze, Anne-Sophie Alary, et al.Liver International : Official Journal of the International Association for the Study of the Liver|September 14, 2021
Late presentation for HCV care: Time to target people with diabetes and/or hazardous alcohol use (ANRS CO22 HEPATHER cohort)Melina Santos, Camelia Protopopescu, Elizabeth Delarocque-Astagneau, et al.Drug Safety|December 4, 2025
Hepatic Effects, Potential Drug-Induced Liver Injury, and Other Liver Safety Considerations of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in the New Era of Expanding Non-oncology Indications: Literature Review and Expert ConsensusAnna Fettiplace, Arie Regev, Alexandre Kiazand, et al.Pageof 14